AFM
ELVN icon

Anson Funds Management’s Enliven Therapeutics ELVN Stock Holding History

Anson Funds Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,089
Closed -$65K – 236
2022
Q3 		$65K Buy
+7,089
New +$41.8K 0.01% 267

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Anson Funds Management's ELVN Position: Q4 2022 in Review

Anson Funds Management sold out of Enliven Therapeutics (ELVN) in Q4 2022, closing a stake of 7,089 shares — an estimated $65K sold.

Anson Funds Management first reported a position in ELVN in Q3 2022 and held it in 1 quarter. The position peaked at $65K in Q3 2022. 36 funds tracked by Wall St. Rank hold ELVN as of Q4 2022.

  • Anson Funds Management reported no remaining Enliven Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Anson Funds Management sold 7,089 Enliven Therapeutics shares in Q4 2022, an estimated $65K.
  • Anson Funds Management first reported a position in Enliven Therapeutics in Q3 2022 and held it in 1 quarter.
  • Anson Funds Management's Enliven Therapeutics position peaked at $65K in Q3 2022.
  • 36 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2022.

Based on Anson Funds Management's 13F filing for Q4 2022, filed 13 Feb 2023.